Adzynma (ADAMTS13, recombinant-krhn) – New orphan drug approval
November 9, 2023 - The FDA announced the approval of Takeda’s Adzynma (ADAMTS13, recombinant-krhn), for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
Top